Tesamorelin increased rectus muscle density by 3.5 units in people with HIV and belly fat, which is about the same difference seen between people with and without back pain in other research.

People with HIV and belly fat who responded to tesamorelin by losing belly fat saw their rectus and psoas muscles grow 0.44 cm² and 0.46 cm² larger than those on placebo after 26 weeks of treatment.

Tesamorelin increased rectus lean muscle by 0.85 cm² in people with HIV and belly fat, and this effect stayed strong even after considering belly fat loss.

People with HIV and belly fat who responded to tesamorelin by losing belly fat saw their trunk muscles grow larger in specific areas: rectus abdominis by 0.85 cm², psoas by 0.64 cm², and others by up to 1.08 cm² more than those on placebo after 26 weeks.

HIV patients with belly fat who responded to tesamorelin had bigger rectus and psoas muscles (0.44 and 0.46 cm² larger) compared to placebo after 26 weeks.

Tesamorelin increased rectus and psoas muscle size by 0.44 and 0.46 cm² in people with HIV and belly fat, and this effect remained even after accounting for belly fat loss.